Apellis finds that one of its twins is evil
A hit and a miss with pegcetacoplan in late-stage trials leaves Apellis with shrinking prospects.
Outlook heads to regulators with eye-friendly Avastin
But questions remain about both the Norse Two trial and the commercial opportunity.
Biotech’s important upcoming data
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Key third-quarter readouts for big pharma
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
No land grab for Gemini in geographic atrophy
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
Clearside’s long-acting eye project shows promise
But data are early, and other groups are also developing less frequent injections for wet AMD.
